Drugs / mitumprotimut-T
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00089115 | Jul 2004 → ? | lymphoma | Favrille | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mitumprotimut-T | “PURPOSE: To evaluate patient-specific immunotherapy with mitumprotimut-T (idiotype keyhole limpet hemocyanin [Id-KLH]) and granulocyte-macrophage colony-stimulating factor...” PMID 19414675 ↗ May 2009 |
| Action | Deplete | “Vaccines made from a person's cancer cells may make the body build an immune response to kill cancer cells.” NCT00089115 ↗ |
| Modality | Vaccine | “autologous immunoglobulin idiotype-KLH conjugate vaccine subcutaneously (SC) on day 1” NCT00089115 ↗ |
| Route | Subcutaneous | “autologous immunoglobulin idiotype-KLH conjugate vaccine subcutaneously (SC) on day 1” NCT00089115 ↗ |